Please login to the form below
37
Revenue 2017Invega Sustenna/Xeplion/Invega Trinza
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Invega Sustenna/Xeplion/Invega Trinza was produced by Roche.
J&J files three-monthly schizophrenia drug in Europe
J&J sells a once-monthly version of paliperidone as Invega Sustenna in the US and Xeplion in Europe, but the reduced dosing frequency could give the franchise a competitive advantage ... Xeplion/Invega Sustenna is already a big earner for J&J, with sales
FDA approves J&J’s schizophrenia drug Invega Trinza
The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Invega Sustenna, which is marketed as Xeplion in Europe, saw its 2014 sales grow by 27% to $1.6bn and J&J will be hopig Invega Trinza will
1
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Moving annual total (MAT)
- GSK hires Merck KGaA exec to lead US pharma business
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Leaked no-deal Brexit document forecasts widespread shortages
- Novartis chooses internal replacement for US pharma president role
- Empowered patients: shaking the foundations of healthcare
- Roche’s Hemlibra scores broader NHS funding
- AZ’s Imfinzi combo bombs again in non-small cell lung cancer
- NICE’s fast-track catapults Skyrizi into market
- GSK files anaemia drug daprodustat in Japan, its first market
- A uniquely English genomic medicine service
PMHub
Star
We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
